Abstract
The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.
Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases
Current Pharmaceutical Design
Title: Bradykinin Antagonists as Anti-Cancer Agents
Volume: 9 Issue: 25
Author(s): J. M. Stewart
Affiliation:
Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases
Abstract: The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.
Export Options
About this article
Cite this article as:
Stewart M. J., Bradykinin Antagonists as Anti-Cancer Agents, Current Pharmaceutical Design 2003; 9 (25) . https://dx.doi.org/10.2174/1381612033454171
DOI https://dx.doi.org/10.2174/1381612033454171 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Hormonal Therapy for Prostate Cancer: Toward Further Unraveling of Androgen Receptor Function
Anti-Cancer Agents in Medicinal Chemistry Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Differential Desensitization of Somatostatin Receptor Subtypes in AtT-20 Cells
Protein & Peptide Letters Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics Synthesis and In Vitro Biological Evaluation of Novel Pyrazole Derivatives as Potential Antitumor Agents
Medicinal Chemistry Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Cellular Relationships of Testicular Germ Cell Tumors Determined by Partial Canonical Correlation Analysis of Gene Expression Signatures
Current Bioinformatics Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry Lipids and Their Derivatives: By-Products Used as Essential Building Blocks for Modern Drug Delivery Systems
Current Drug Targets Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy Androgen Receptor Antagonists in the Treatment of Prostate Cancer
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Morphological Characteristics, Geographical Distribution, Secondary Metabolites, and Biological Activities of Taxus
Mini-Reviews in Organic Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Vitamin D in COPD - A Pleiotropic Micronutrient in a Multisystem Disease
Current Respiratory Medicine Reviews Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination
Current Topics in Medicinal Chemistry